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Abstract
Some secondary metabolites from plants show to have potent inhibitory activities against microbial pathogens, such as
human immunodeficiency virus (HIV), herpes simplex virus (HSV), Treponema pallidum, Neisseria gonorrhoeae, etc. Here we
report that lignosulfonic acid (LSA), a polymeric lignin derivative, exhibits potent and broad activity against HIV-1 isolates of
diverse subtypes including two North America strains and a number of Chinese clinical isolates values ranging from 21.4 to
633 nM. Distinct from other polyanions, LSA functions as an entry inhibitor with multiple targets on viral gp120 as well as on
host receptor CD4 and co-receptors CCR5/CXCR4. LSA blocks viral entry as determined by time-of-drug addiction and cell-
cell fusion assays. Moreover, LSA inhibits CD4-gp120 interaction by blocking the binding of antibodies specific for CD4-
binding sites (CD4bs) and for the V3 loop of gp120. Similarly, LSA interacts with CCR5 and CXCR4 via its inhibition of specific
anti-CCR5 and anti-CXCR4 antibodies, respectively. Interestingly, the combination of LSA with AZT and Nevirapine exhibits
synergism in viral inhibition. For the purpose of microbicide development, LSA displays low in vitro cytotoxicity to human
genital tract epithelial cells, does not stimulate NF-kB activation and has no significant up-regulation of IL-1a/b and IL-8 as
compared with N-9. Lastly, LSA shows no adverse effect on the epithelial integrity and the junctional protein expression.
Taken together, our findings suggest that LSA can be a potential candidate for tropical microbicide.
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Introduction
Since the advent of AIDS pandemic, efforts have been directed
to the search of viral inhibitory molecules to either block virus at
the entry portal or disrupt viral life cycle after the entry.
Tremendous progress has been made in drugs that inhibit virus
through disrupting reverse transcription, integration or proteolytic
processing of viral proteins, which witness the introduction of
nucleoside analog reverse transcriptase inhibitors (NRTIs), non-
nucleoside analog reverse transcriptase inhibitors (NNRTIs),
integrase inhibitors and protease inhibitors as Highly Active
Antiretroviral Therapy (HAART). The introduction of HAART
can effectively keep the viral replication at an undetectable level,
thus prolong the life expectancy of the infected and reduce the
viral transmission. Comparatively, fewer agents that inhibit viral
entry have made to the market.
The infection of HIV-1 is initiated by the viral envelop
interaction specifically with its cellular receptor CD4, which leads
to further interaction with viral co-receptor CCR5 or CXCR4
[1,2]. The binding processes are coordinated by HIV-1 envelop
conformational changes that are essential for the virus-cell fusion
to proceed to productive infection of the host cells [1,2]. Evidence
also suggested that the nonspecific interactions of viral particles
and cell surface molecules, such as the heparan sulfate moiety of
proteoglycans and cell surface adherent molecules, also play
important roles in viral attachment and entry [3]. It is well
established that sulfated polyanions (SPs) are potent inhibitors of
HIV infection by either competing with cell surface molecules for
virus binding or directly interacting with cell surface molecules
that are required for the virion attachment or entry [4]. These
negatively charged molecules can bind HIV-1 envelop glycopro-
teins, and cell surface molecules, such as CD4 on the lymphocytes,
through charge-charge interactions and thus disrupt viral binding
or fusion process [5–7]. Heparan and its chemical derivatives were
found to inhibit HIV and HSV infection, through binding to viral
proteins and probably disrupting the attachment and entry
processes [8,9]. In the case of HSV-1, the heparan sulfate binding
to viral gD protein is rather specifically mediated by 3-O-sulfated
GlcNp residue that is essential for HSV-1 to penetrate host cells
[10]. Another extensively investigated SP is dextran sulfate [8] that
potently inhibited HIV-1 replication in cultured CD4+ lympho-
blastoid cell lines [4]. Mechanistic studies showed that dextran
sulfate may act on both virions [11] and target cells [5]. The V3
loop has been reported to be a major HIV-1 region directly
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interacting with SPs [5], [11–15], though other sequences located
in the V2, CD4 binding site (CD4bs) and C-terminus of gp120
were also described [16]. SPs’ binding to cell-associated molecules
were also reported and considered to play roles in viral inhibition
as well [5–7,17,18].
Many of the reported SPs have a linear polysaccharide backbone
with varying degrees of sulfation. Current study reported an HIV-1
inhibiting macromolecule that constitutes three-dimensional scaf-
fold polymers composed of sulfated phenylpropanoid monomers.
Macromolecular lignin sulfonate presents a multitude of poly-
dispersity that can interact with biomolecules through hydrophobic,
hydrogen-bonding, and anionic interactions as other sulfated
polyanions (dextran sulfate, heparan sulfate, etc.). Our evidence
showed that the polymers may exert the HIV inhibitory activity
through multiple bindings with both viral and cell surface molecules
and present as potentialHIV inhibitors on viral attachment or entry.
Results
LSA inhibition of HIV-1 infection in vitro and synergism
with AZT and nevirapine
The antiviral activity of LSA was tested against two laboratory-
adapted HIV-1 strains and a number of clinical isolates on Ghost
(3) X4/Hi5 cells using an Env-pseudotyped infection assay. LSA
was shown to inhibit both JR-FL (R5-type) and HXB2 (X4-type) at
an EC50 of 6.323 mg/ml and 1.411 mg/ml, respectively (Table 1).
LSA also exhibited inhibitory activities against a panel of diverse
clinical isolates derived from infected Chinese patients [19], with
EC50 values ranging from 0.171 mg/ml to 5.060 mg/ml (Table 1).
For all the isolates tested, the EC50 values, ranged from 0.171 mg/
ml to 6.323 mg/ml, were well below the CC50 cytotoxicity values
determined in the corresponding cells (Table 2). In contrast, LSA
did not have significant inhibitory activity against VSV-G
pseudovirus. LA, a LSA precursor, showed less inhibitory activity
against all strains (data not shown), demonstrating that sulfonic
groups are critical for the antiviral activity.
We also investigated the inhibitory activities of LSA in
combination with RT inhibitors and analyzed their synergistic
effects. As shown in Table 3, the combination of LSA with AZT (an
NRTI) or nevirapine (an NNRTI) exhibited moderate synergism
against JR-FL and synergism against HXB2, respectively.
The inhibitory mechanism of LSA
The time-of-drug-addition assay was performed to investigate
the inhibitory mechanism of LSA. For comparison, two RT
inhibitors, AZT and nevirapine, and an entry inhibitor, dextran
sulfate, were used. As shown in Figure 1A, LSA exhibited the
similar inhibitory profile as dextran sulfate, but distinct from both
RT inhibitors. Viral infection was completely blocked when LSA
was added at 1 hour postinfection but significant infection was
detected when LSA was added in 2 hour postinfection. As
expected, both AZT and nevirapine completely suppressed viral
infection when added until 8 hours postinfection. These results
demonstrated that LSA inhibited virus at an early stage during
binding and entry. We also investigated the activity of LSA in
inhibiting gp120-mediated membrane fusion. As shown in
Figure 1B, LSA inhibited cell-cell fusion between gp160 expressing
CHO-WT cells and MT-2 cells in a dose-dependent manner.
We also determined that LSA could block sCD4 binding to
immobilized gp120s (shown in Figure 1C) while LA failed to
inhibit at the same molar concentration. However, our data
showed differential inhibitory activities against gp120ADA and
gp120IIIB primarily in that LSA appeared more efficient in
blocking gp120ADA than gp120IIIB from binding to sCD4.
Whether LSA inhibited HIV-1 virion attachment to cells was
also studied. The results showed that LSA inhibition of HIV-1
virion attachment was minimal, even at the highest concentration
of 200 mg/ml in either CD4-positive Ghost cells or CD4-negative
cervical cells, as shown in Figure 1D. Heparan sulfate at 100 mg/
ml (HS), serving as a control, exhibited only 30%–50% inhibition
against JR-FL and HXB2, consistent with previous report [15].
LSA inhibited antibody binding to the V3 loop and CD4
binding site on gp120
Studies have demonstrated that the V3 loop on HIV-1 Env is
a major region interacting with sulfated polysaccharides via
charge-charge interaction [5,11,12,14,15,20], though other re-
gions of gp120 may also involve [16]. LSA was investigated for its
effect on a panel of neutralizing mAb binding to gp120 by ELISA.
V3 specific mAb 447–52D binding to gp120s was significantly
reduced by LSA in a dose-dependent manner. Similarly, 447–52D
binding to synthetic linear V3 peptides derived from JR-FL and
IIIB was also blocked (data not shown). 2G12, a broadly
neutralizing mAb specific for mannose carbohydrates, was not
significantly inhibited by LSA in its binding to gp120ADA and
gp120IIIB but significantly inhibited in binding to gp120YU2. The
effective inhibition of 2G12 binding to gp120YU-2 by LSA
probably attributes to the fact that gp120YU-2 lacks a critical
glycan required for efficient 2G12 binding causing reduced 2G12
binding affinity [21], which allows more efficient LSA blocking.
CD4bs mAb b12 was also inhibited by LSA (Figure 2).
LSA interacted with cellular CD4 and ECL2 of CCR5/
CXCR4
We also investigated whether LSA interacted with cell surface
CD4 and viral co-receptors. The bindings of four anti-CD4 mAbs
(RPA-T4, Leu-3a, 34930 and OKT4) to CD4-expressing MT-2
cells were analyzed in the presence or absence of LSA by FACS.
Leu-3a, RPA-T4 and 34930 are HIV-1 neutralizing antibodies,
recognizing distinct epitopes. Leu-3a recognizes D1 domain of CD4
at the site overlapping the CDR2 region and RPA-T4 binds the
CDR1 and CDR3 while the epitope for 34930 is yet to be defined.
OKT4 recognizes an epitope on D3 domain of CD4 and does not
block HIV-1 entry. A dose-dependent reduction of the binding of
RPA-T4 and34930was observed in the presence of LSAas shown in
Figure 3. Both RPA-T4 and 34930 binding to MT-2 cells was
inhibited by more than 80% at 200 mg/ml LSA while Leu-3a was
inhibited by 50% only at the highest concentration of 200 ug/ml. In
contrast, LSA showed no effect on OKT4 binding.
Table 1. LSA inhibition of HIV-1 pseudotyped virus infection
of Ghost (3) X4/Hi5 cells.
Virus Tropism subtype EC50 (mg/ml) EC90 (mg/ml)
JR-FL CCR5-tropic B 6.323 17.047
HXB2 CXCR4-tropic B 1.411 3.700
CNE6 CCR5-tropic B’ 0.717 2.764
CNE30 CCR5-tropic B’C 5.055 8.280
CNE50 dual tropic B’C 0.171 13.455
CNE55 CCR5-tropic CRF01-AE 2.710 8.019
VSVG
pseudovirus
– – 39.701 .90
doi:10.1371/journal.pone.0035906.t001
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mAbs specific for the N-terminals and extracellular loop 2
(ECL2) of the co-receptors were chosen to investigate whether
their bindings to Ghost (3) X4/Hi5 cells were inhibited by LSA
since these two regions are most important for HIV-1 gp120
binding and viral entry [22]. Firstly, we examined the inhibitory
effect of LSA on the binding of a number of HIV-1 inhibitory
mAbs to CCR5 (Figure 4A). mAbs 2D7 and 45531 recognize the
N-terminal of ECL2 (ECL2A) and the C-terminal of ECL2
(ECL2B), respectively, while mAb T21/8 recognizes the N-
terminal of CCR5. mAb 45549 is reactive to multi-domains of
CCR5. LSA slightly reduced only mAb 45531 binding to CCR5
(46.4% inhibition) at the highest concentration and had no effect
on other mAbs. Nifeviroc, a CCR5 antagonist, used as a positive
control, showed strong inhibitory activity on 2D7 and 45531
binding.
LSA significantly blocked 12G5 binding to CXCR4 while
showed no significant effect on 4G10, as shown in Figure 4B.
12G5 recognizes an epitope overlapping ECL2 of CXCR4 and
4G10 is specific for the N-terminal of CXCR4. AMD3100,
a CXCR4 antagonist, was used as the positive control and
exhibited potent inhibition of 12G5 binding.
LSA was characterized by low cytotoxicity in vitro
The in vitro cytotoxicity of LSA was analyzed on human vaginal
and cervical epithelial cell lines (VK2/E6E7 and C33-A), Caco-2,
human T-cell leukemia cells (MT-2) and indicator cells (Ghost (3)
X4/Hi5), respectively. For all 5 cell lines tested, LSA showed low
cytotoxicity with CC50 values ranging from 308 to 1147 mg/ml
(Table 2), presenting appreciable Therapeutic Indexes as a poten-
tial antiviral drug.
LSA also did not elevate IL-1a and IL-8 expression above its
basal level, as shown in Figure 5A, although slightly up-regulate
IL-1b, which might be caused by LSA acute cytotoxicity. N-9,
a surfactant and the first microbicide candidate, served as the
positive control and showed significant up-regulation of IL-1a/
b and IL-8 in VK2/E6E7 cells. Overall, LSA did not alter
cytokines/chemokines profile of genital epithelial cells significantly
in comparison with N-9.
The effect of LSA on NF-kB activation in genital tract epithelial
cells was also investigated. We did not find that NF-kB activity in
VK2/E6E7 cells was augmented after 24 hours LSA treatment, in
contrast to the N-9 treatment that NF-kB activated luciferase
expression was significantly elevated (Figure 5B).
LSA did not cause the destruction of epithelium integrity
For topical antiviral application, low toxicity and none
disruptive to mucosal epithelium of the antiviral agent are
considered critical. Therefore, we investigated whether LSA
would affect tight junction protein expression important for the
integrity of epithelium using HEC-1-A and Caco-2 cells. HEC-1-A
and Caco-2 cells were treated with serial concentrations of LSA or
100 ng/ml TNF-a (as a positive control) for 6, 24 and 48 hours,
and target protein expressions were analyzed by qRT-PCR.
6 hour-treatment did not affect tight junction protein expression,
as shown in Figure 6A. After 24 hours exposure to LSA, ZO-1 and
occluding expressions were not affected significantly in both cells,
while E-cadherin was markedly up-regulated in HEC-1-A cells.
Similarly, the genes for the three proteins were not down-regulated
significantly in the presence of LSA in comparison with TNF-
a which down-regulated the expressions of all three proteins after
48 hours treatment.
We also investigated the effects of LSA on the epithelial
permeability by evaluating Lucifer Yellow leakage in HEC-1-A
and Caco-2 cells. As shown in Figure 6B, LSA did not increase
Lucifer Yellow leakage in HEC-1-A and Caco-2 cell monolayers
compared with the mock wells which were not exposed to the
drugs. Cell monolayers which were incubated with 100 ng/ml
TNF-a were more permissive for leakage of Lucifer Yellow,
consistent with a previous report [23]. In conclusion, LSA did not
compromise the integrity of epithelial cell monolayers at non-
cytotoxic concentration.
Discussion
Lignin is a polymeric natural product derived from wood, and
an integral part of the secondary cell walls of all terrestrial plants.
Unlike heparan sulfate, a linear copolymer of glucosamine (GlcNp)
and glucuronic acid (GlcAp) linked in a1–4 manner. Sulfated
lignin is a three-dimensional scaffold polymer composed of
substituted phenylpropanoid monomers. Macromolecular lignin
sulfate presents a multitude of polydispersity that can interact with
biomolecules through hydrophobic, hydrogen-bonding, and
anionic interactions. In this report, we presented studies on
inhibitory activities of the sulfated lignin against various HIV-1
isolates, its mechanisms of action and in vitro cytotoxicity.
Six HIV-1 isolates (JR-FL, HXB2, CNE6, CNE30, CNE50,
and CNE55) representing clades B, B’, B’C and AE recombinant
Table 2. CC50 values of cytotoxicity of LSA in human cell lines.
Cell line CC50 value (mg/ml)
MT-2 (human T-cell leukemia cells) 308.64
C33-A (human cervical carcinoma cells) 420.78
Caco-2 (human epithelial colorectal adenocarcinoma cells) 1147.23
Ghost (3) X4/Hi5 (derived from HOS cells) 726.34
VK2/E6E7 (human vaginal epithelial cells) 690.45
doi:10.1371/journal.pone.0035906.t002
Table 3. CIs for LSA with AZT or nevirapine in Ghost (3) X4/
Hi5 cells infected with JR-FL and HXB2 strains.
Combination Weight Ratio CIa at 50% inhibition of HIV-1
JR-FL HXB2
LSA/AZT 7666.7:1 0.836 0.445
LSA/nevirapine 230:1 0.743 0.609
a. CI ,0.1: very strong synergism; 0.1–0.3: strong synergism; 0.3–0.7: synergism;
0.7–0.85: moderate synergism; 0.85–0.90: slight synergism; 0.9-1.1: Nearly
additive and .1.1: antagonism.
doi:10.1371/journal.pone.0035906.t003
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Figure 1. LSA inhibited HIV-1 infection at viral entry stage. A. Time-of-drug-addition assay indicated that LSA blocked HIV-1 infection at an
entry stage. B. MT-2-CHO-WT Cell-cell fusion was inhibited in the presence of LSA. C. LSA, not LA blocked sCD4 binding to rgp120s from ADA and IIIB
strains. D. LSA inhibited JR-FL and HXB2 HIV-1 virion attachment to Ghost (3) X4/Hi5 and HEC-1-A cells. Heparan sulfate (100 mg/ml) was used as
a control. Data shown were the average of three independent experiments. Error bars denoted standard errors of the mean values.
doi:10.1371/journal.pone.0035906.g001
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viral subtypes were chosen for the inhibitory study. JR-FL,
a CCR5-tropic virus, and HXB2, an CXCR4-tropic virus, were
well-characterized isolates derived from North American subtype
B while all CNE viruses were derived from circulating isolates
from Chinese patients [19]. LSA exhibited potent inhibitory
activities against all six HIV-1 isolates (Table 1). In contrast to
dextran sulfate [24], we did not found great differential inhibitory
activities against X4 and R5 viruses, suggesting that the V3 charge
is not the only determinant for LSA activity, which is consistent
with the fact that LSA binds multiple sites on gp120. In addition,
LSA, in combination with AZT or nevirapine, exhibited synergism
or modest synergism against HIV-1JR-FL and HIV-1HXB2 strains,
which broaden PSM potential application as an antiviral agent in
combination with other drugs.
Time-of-drug-addition study suggests that LSA exerted its
inhibitory activity at an early stage of viral entry with a window
time of about 2 hours and that the LSA inhibitory profile
overlapped with that of dextran sulfate. The LSA inhibition of
HIV-mediated syncytia formation further demonstrated that LSA
is an entry inhibitor, consistent with current understanding on the
inhibitory mechanisms of sulfated polysaccharides [15,25–27].
The V3 domain has been shown previously to be a major Env
determinant interacting with sulfated polysaccharides through
charge-mediated interaction [11]. Our study showed that the
binding of 447-52D, a neutralizing anti-V3 mAb was inhibited by
LSA in a dose-dependent manner, suggesting that the positively
charged LSA is likely interacting with the negatively charged V3
loop sequence. The lack of LA, a derivative that lacks sulfonic
moiety, in inhibitory activity further supports the view that charge-
mediated interaction plays important roles. This observation
suggested that LSA is distinct from dextran sulfate that was
previously shown not to inhibit 447-52D binding to gp120 [28].
The current study also showed that LSA interacted with CD4bs on
gp120. CD4bs antibody F105 was almost completely blocked from
binding to gp120 by LSA. b12, another CD4bs mAb, was also
inhibited by LSA for binding to gp120, consistent with the
observation that LSA blocked sCD4 binding to gp120s. LSA
effectively blocks 12G5 binding to CXCR4 but only slightly
inhibited mAb 45531 binding to CCR5. It is unlikely that blocking
of 12G5 binding was caused by LSA binding to the antibody since
4G10, recognizing the N-terminus of CXCR4, was not affected by
LSA. Moulard et al. [28] reported that dextran sulfate also blocked
12G5 binding to CXCR4 and found that CXCR4 virus was
significantly more sensitive to dextran sulfate inhibition in vitro.
However, we did not observe consistently differential inhibition of
X4 and R5 virus infections by LSA. Together, the analysis of LSA
inhibition of mab binding to gp120, CD4 and coreceptors suggests
that LSA inhibition is likely mediated by binding to multiple
targets, consistent with its three dimensional scaffold structure.
However, we observed that LSA only slightly inhibited virion
attachment to both CD4-positive and -negative cells. Monder et al.
[29] observed that HIV-1 attachment was minimally influenced by
the presence of cellular CD4 and suggested that nonspecific
cellular adhesion molecules may play important roles in mediating
initial virus-cell interaction to bring virions to the CD4 proximity
to form high affinity binding. Our data are consistent with
Figure 2. The effect of LSA on the gp120-specific mAb binding. gp120-specific mAbs were incubated in the presence of various
concentrations of LSA with immobilized gp120IIIB (A), gp120ADA (B) or gp120YU-2 (C) in a 96-well plate. AP-conjugated anti-human secondary antibody
was added after excess LSA and the first antibodies were removed. The results were presented as the percentage of mAb binding. Each datum point
was the means of triplicate and the experiment was repeated 3 times. A typical experiment was shown. Error bars denote standard error of the mean
values.
doi:10.1371/journal.pone.0035906.g002
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Monder’s observation. Several studies have reported that SPs
inhibited HIV-1 infection by disrupting the interaction between
gp120 and CD4, by either binding to CD4 [5,7] or to gp120
[16,28]. Lynch et al. [6] reported that dextran sulfate and other
SPs prevented HIV-1 infection by disrupting the interaction
between gp120 and CD4 molecules and suggested that the SP
binding to CD4 is the predominant mechanism of inhibition.
Lynch et al. [6] failed to detect SP-rgp120 binding but reported
weak interaction between SP and a V3 peptide. Crublet et al. [16]
mapped four gp120 domains that interacted with heparan sulfate,
V2, V3, a bridging sheet induced by CD4 binding and a sequence
at the C-terminus of gp120. Harrop et al. [30] reported that
heparan sulfate interacted with viral gp120 rather than the
receptor-CD4.
To facilitate our understanding on how LSA might interact with
its target molecules and exert its viral inhibitory activity, we
generated a computer-aided three dimensional structure of LSA
and docked the structure with the complete structures of both
gp120JR-FL and gp120HXB2 that were reconstructed by homology
modeling using published data [31], as shown in Figure 7. The
docking analysis suggested that the most stable and optimized
docking was LSA in complex with the tip of V3 loop, which
predicted that LSA would create a steric clash for the interacting
V3 mAbs, such as 447–52D. Other possible binding sites were
predicted to be in the vicinity of CD4bs. Even though LSA did not
insert into the pocket of CD4bs, this binding manner might
interfere with the CD4 and anti-CD4bs mAbs binding to this area.
The computational prediction was consistent with experimental
data. The selective inhibitions of mAb bindings to gp120 ruled out
the possibility that the LSA inhibitions were in fact mediated by
LSA binding to mAbs instead of gp120. This conclusion would
also apply to LSA inhibition of mAb binding to CD4 and the co-
receptors CCR5 or CXCR4.
Prophylactic use of therapeutic viral reverse transcriptase
inhibitor has been successfully tested in clinical trials and
demonstrated to be safe and effective in preventing sexual
transmission of HIV-1 [32]. Combination of anti-viral agents
with distinct working mechanisms is considered to provide even
better protection. The synergistic effects of LSA in combination
with a number of RT inhibitors, together with low toxicity to
epithelial cells, make LSA an interesting candidate as a topical
microbicide. Topical application will avoid the shortfalls, such as
poor ability in penetrating blood barriers and toxicity to
lymphocytes [33–36], associated with many SPs [37]. Our
observations that LSA did not disrupt the epithelial monolayer
integrity and decrease the tight junction protein expression and
modulate inflammatory cytokine expression significantly further
support this notion. In addition, our preliminary data showed that
LSA did not disturb the growth of lactobacillus, an important
component of vaginal microflora (data not shown). Together, our
observations suggest that LSA deserve further investigation as
a tropical microbicide candidate.
Figure 3. The effect of LSA on anti-CD4 mAb binding. MT-2 cells were incubated with a panel of CD4-specific mAbs with or without the
presence of various concentrations of LSA for 30 minutes at 4uC. The bindings of the mAbs to the cell surface CD4 were measured by FACS and
expressed as the percentages of mAb binding in the absence of LSA. Error bars represented standard deviations. Each datum point was the means of
the triplicate and the experiment was performed 2–3 times. A representative experiment was shown.
doi:10.1371/journal.pone.0035906.g003
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Methods
Reagents, cell lines and plasmids
Lignosulfonic acid (LSA), lignin alkali (LA), heparan sulfate,
DEAE-dextran, dextran sulfate, azidothymidine (AZT),
AMD3100, gelatin, p-nitrophenyl phosphate (p-NPP), N-9 were
purchased from Sigma-Aldrich (St. Louis, USA). Lipofectamine
2000, TRIzol, Lucifer Yellow were from Invitrogen (Carlsbad,
USA). Nevirapine was obtained from National Institutes for Food
and Drug Control in China (Beijing, China). Nifeviroc was a kind
Figure 4. The effect of LSA on the anti-CCR5/CXCR4 mAb binding. CCR5-specific mAb binding to Ghost (3) X4/Hi5 cells (A) were inhibited by
LSA (dashed block) or Nifeviroc, a CCR5 antagonist serving as a control (solid block), or CXCR4-specific mAb bindings to Ghost (3) X4/Hi5 cells (B) were
inhibited by LSA (dashed block) or AMD3100, a CXCR4 antagonist serving as a control (solid block). Ghost (3) X4/Hi5 cells in suspension were
incubated with anti-CCR5/CXCR4 mAbs in the presence of various concentrations of LSA or Nifeviroc for 30 minutes at 4uC. The binding of the mAbs
to the cell surface co-receptors was measured by FACS. Data shown were the average of three independent experiments. Error bars denote standard
errors of individuals.
doi:10.1371/journal.pone.0035906.g004
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Figure 5. LSA effect on NF-kB activation and modulation of IL-8 production. A. IL-1a/b and IL-8 secretions by VK2/E6E7 cells after exposure
to LSA for 6 hours. B. Quantification of NF-kB activation in VK2/E6E7 cells post-incubation with various concentration of LSA using a NF-kB luciferase
reporter plasmid. N-9 (10 mg/ml) was used as a positive control for the stimulation of NF-kB, cytokines and chemokines productions. *: P,0.05 and **:
P,0.01.
doi:10.1371/journal.pone.0035906.g005
Figure 6. LSA did not destroy epithelium integration. A. ZO-1, E-cadherin and occludin expressions in HEC-1-A and Caco-2 cells after LSA
treatment for 6, 24 and 48 hours. B. Lucifer Yellow leakage through HEC-1-A or Caco-2 monolayers after treatment with serial concentrations of PSM
for 48 hours. TNF-a treatment (100 ng/ml) was used as a positive control. Each datum point was mean of triplicate and the experiment was repeated
twice. A representative experiment was shown. *: P,0.05 and **: P,0.01.
doi:10.1371/journal.pone.0035906.g006
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gift from Shanghai Target Drug Ltd. (Shanghai, China). Cell
counting kit-8 (CCK-8) was purchased from Dojindo Laboratories
(Kumamoto, Japan). Glo Lysis buffer and luciferase assay kit were
obtained from Promega Bio-technology (Madison, USA). Recom-
binant gp120s (rgp120s) and soluble CD4 (sCD4) and were
purchased from Immunodiagnostics, Inc. (Woburn, USA). The
HIV p24 ELISA kit was purchased from Shanghai Qifa Biotech
Ltd. (Shanghai, China). gp120-specific monoclonal antibodies
(mAbs) b12, 2G12, 447-52D and F105 were from AIDS Research
and Reference Reagent Program, National Institute of Health
(NIH, USA). Anti-CD4 mAb RPA-T4, anti-CCR5 mAb 2D7 and
anti-CXCR4 12G5 were purchased from BD Biosciences (San
Jose, USA). Human rTNF-a, anti-CD4 mAb 34930, anti-CCR5
mAbs 45531 and 45549 and normal human IgG control were
from R&D Systems (Minneapolis, USA). Anti-CD4 mAb OKT4
and PE-labelled Leu-3a, goat-anti-human IgG FITC, goat-anti-
mouse IgG FITC, purified mouse IgG1/IgG2a/IgG2b isotype
control and IL-1a/b and IL-8 ELISA kits were obtained from
eBioscience (San Diego, USA). Anti-CCR5 mAb T21/8 and anti-
CXCR4 mAb 4G10 were purchased from Santa Cruz Bio-
technology (Santa Cruz, USA). Alkaline phosphatase labeled goat-
anti-human and goat-anti-mouse IgG was purchased from Zymed
(South San Francisco, USA).
HEC-293T, VK2/E6E7, Caco-2 and C33-A cells were
purchased from American Type Culture Collection (ATCC).
Ghost (3) X4/Hi5, MT-2 and CHO-WT cells were obtained from
AIDS Research and Reference Reagent Program, NIH. Plasmid
pNL4-3 E-R- Luc and HIV-1/VSV-G Env were kindly provided
by Dr. Linqi Zhang at Tsinghua University, China. NF-kB-luc
reporter plasmid was purchased from Clotech (Palo Alto, USA).
Antiviral activity assay
The Env-pseudotyped viruses were produced by transient co-
transfection of HEC-293T cells with pNL4-3 E-R- Luc and Env-
encoding plasmids as reported [24,38], and the 50% tissue culture
infective dose (TCID50) of infectious pseudovirions was de-
termined as reported previously [39,40]. Compounds against
pseudotyped HIV-1 virus were determined as described [40].
Briefly, cultural medium containing serially diluted LSA was
mixed with 200 TCID50 pseudovirus in 96-well plates and
incubated for 30 min. All drug dilutions were in triplicate. 104
cells in 100 ml medium containing DEAE-dextran (final concen-
tration 5 mg/ml) were dispensed to each well and the plates were
incubated for 48 hours. The level of viral infection was quantified
by measurement of relative luminescence units (RLU) using
luciferase assay kit by GloMax-96 Microplate Luminometer
(Promega, Madison, USA). The half maximal effective concen-
tration (EC50) were calculated using CalcuSyn software [41].
Synergy analysis
AZT, nevirapine and LSA were tested individually in series
concentrations in Ghost (3) Hi5/X4 cells and the EC50 values of
the single drugs were calculated. Two drugs (AZT/LSA and
nevirapine/LSA) combinations were tested at a fixed weight
concentration ratio, which was optimized to give the greatest
synergism over a range of serial dilutions. The EC50 values of
single drugs and the combination index (CI) of the two drugs were
Figure 7. Molecular modelling of two optimal docking predictions. A. Docking prediction of LSA surrounding gp120 V3 loop. B. Details of
the interaction between V3 loop and LSA molecule (four amino acids G-P-G-R displayed in CPK mode interacting with LSA molecule). C. Docking
prediction showing LSA binding to the proximity of CD4 binding site (CDbs) (the CD4bs residues, Glu370, Ile371, Trp427, Val430 and Gly473, were
labeled by CPK mode). D. LSA might block or interfere CD4 binding to gp120. Red, cyan and yellow represented CD4 molecule, gp120 and LSA
molecule, respectively.
doi:10.1371/journal.pone.0035906.g007
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calculated using CalcuSyn software [41] according to the method
of Chou-Talalay [42]. The synergy was estimated by CI values
[42].
in vitro cytotoxicity assay
The in vitro cytotoxicity of LSA was measured on various cell
lines using CCK-8 kit in accordance with the manufacturer’s
instruction. Briefly, 104 cells/well were seeded into 96-well plates
and cultured overnight. Drugs in serial concentrations were added
in triplicate, and the cell culture was kept for 48 hours. 10 ml
CCK-8 working solution was then added into each well and the
plates were incubated for 4 hours and OD values were measured
at 450 nm using TECAN Infinite M200 microplate reader
(Ma¨nnedorf, Switzerland). The 50% cytotoxicity concentrations
(CC50) were calculated using CalcuSyn [41].
Time-of-drug-addition assay
A time-of-drug-addition assay was performed as described
elsewhere [43] to investigate the mechanism of the LSA antiviral
activity when the drug was added at various time points after virus
infection. Briefly, 104 Ghost (3) X4/Hi5 cells cultured overnight
were incubated with 200 TCID50 JR-FL viruses in 96-well plates.
Test compounds or culture medium alone (negative control) were
added at different time points post viral infection. Dextran sulfate
was used at 100 mg/ml, nevirapine at 2 mg/ml, AZT at 0.5 mg/
ml, and LSA at 40 mg/ml. The RLUs were measured as described
above.
Inhibition of cell-cell fusion
Inhibition of fusion of MT-2 cells (CD4+ CXCR4+) and CHO-
WT cells stably transfected with HIV-1 gp160 was determined
using a syncytium formation assay [44] with modifications. Briefly,
56105 gp160-expressing CHO-WT cells were mixed and in-
cubated with an equal number of MT-2 cells in the presence or
absence of LSA in serial concentrations for 24 hours. The
monolayers were fixed with 10% formaldehyde-PBS for 3 minutes
and stained with Giemsa dye. The syncytia were counted under
inverted microscope.
Inhibition of sCD4 binding to rgp120s
The effects of LSA on sCD4 binding to gp120 were analyzed by
solid phase enzyme-linked immunosorbent assay (ELISA). 8 mg/
ml gp120 in 50 ml 0.1 M NaHCO3 (pH 9.6) was coated to 96-well
plate at 4uC overnight. The plate was then blocked with 3%
nonfat dry milk in TS buffer (0.14 M NaCl, 0.01 M Tris, pH 7.0)
at 37uC for 1 hour. LSA diluted in TS buffer was added in
duplicate and incubated for 30 minutes, followed by the addition
of 100 ng sCD4 and further incubation at 37uC for 1 hour. After
washing five times with TS buffer, bound sCD4 was detected by
anti-CD4 OKT4 mAbs (2 mg/ml) followed by AP-conjugated
goat-anti-mouse IgG (2 mg/ml). Fifty microliters of p-NPP solution
were added into each well and the absorbance at 405 nm was
measured by a microplate reader.
Interaction of LSA with CD4, CCR5 and CXCR4
To determine the interaction between LSA and CCR5/
CXCR4, Ghost (3) X4/Hi5 cells were digested with 0.5 mM
EDTA and 106 cells were incubated with 2 mg mAbs specific for
CD4, CCR5 or CXCR4 in the presence or absence of LSA at 4uC
for 30 minutes. The cells were washed twice with PBS containing
2% FBS and then stained with 2 mg goat-anti-mouse FITC-
conjugated mAb at 4uC for 30 minutes. For nonspecific control,
cells were stained in parallel with isotype control mAbs. The cells
were then fixed with 2% paraformaldehyde solution and analyzed
with a FACSCalibur (BD, San Jose, USA). The percentage of
mAb binding was calculated based on the mean fluorescence
intensity (MFI).
Interaction of LSA with viral gp120
The interaction between LSA and rgp120s was investigated by
ELISA. Briefly, 96-well plates were coated with 50 ng/well
gp120IIIB or gp120ADA in 0.1 M Tris buffer (pH 8.8) at 4uC
overnight. The plates were washed with TS buffer five times and
blocked with 1mg/ml BSA and gelatin (0.1 mg/ml) in TS buffer at
37uC for 1 hour. Serial concentrations of LSA were added and
incubated, followed by the addition of 10 ng/well mAbs and
secondary antibody as described earlier. Color development was
carried out as described before.
Virion attachment assay
LSA inhibition of virion attachment was performed as pre-
viously described [45], but modified. 56104 HEC-1-A or Ghost (3)
X4/Hi5 cells/well were seeded into a 24-well plate and cultured
overnight. The cell monolayers were then exposed to 50 ng p24
virus solution and incubated in the presence or absence of LSA at
37uC for 1 hour. Addition of 100 mg/ml heparan sulfate was set as
positive control. The cell monolayer was washed five times and
then lysed immediately using 0.5 ml cell lysis buffer (1% NP-40,
100 mg/ml BSA in PBS). The lysate was centrifuged and p24 level
in the supernatant was determined using p24 core antigen ELISA
kit.
RNA extraction and real-time quantitative reverse
transcription polymerase chain reaction (qRT-PCR)
Total RNA was extracted using TRIzol reagent. cDNA was
reverse-transcribed in a 20 ml volume using RT-PCR kit
(TOYOBO, Osaka, Japan). Real-time PCR was performed in
triplicate on ABI Prism 7300 Sequence Detection System using the
SYBR Green PCR Master Mix (TOYOBO, Osaka, Japan)
according to the manufacturer’s protocol. Human ZO-1, E-
cadherin and Claudin mRNA was standardized against house-
keeping gene GAPDH. qPCR Primers were from RTPrimerDB
[46] and listed as follows: ZO-1 Forward AAGTCACACTGGT-
GAAATCC, ZO-1 Reverse CTCTTGCTGCCAAACTATCT;
E-cadherin Forward AGGCCAAGCAGCAGTACATT, E-cad-
herin Reverse ATTCACATCCAGCACATCCA; Occludin Fw
CATTGCCATCTTTGCCTGTG, Occludin Reverse AGCCA-
TAACCATAGCCATAGC; GAPDH Forward TGCACCAC-
CAACTGCTTAGC, GAPDH Reverse GGCATG-
GACTGTGGTCATGAG.
Lucifer yellow leakage assay
Epithelial cell monolayers were prepared in 0.4 mm-pore
Millicell hanging cell culture inserts (Millipore Corporation,
Bedford, USA) in 24-well plates (Corning, New York, USA) as
described [47]. Various LSA doses and 100 ng/ml TNF-a were
pre-incubated in Millicell apical chambers for 48 hours, followed
by two PBS washings of the apical and basolateral chambers.
200 ml 50mg/ml Lucifer Yellow solution, prepared in PBS, was
added to the apical chambers and 1300 ml PBS to the basolateral
ones. Non-cell-layer-inserts were set as mock controls. The plates
were incubated at 37uC, 5%CO2 for 3 hours. Lucifer yellow
leakage into basolateral chambers were measured using Hitachi
F7000 spectrofluorometer (Tokyo, Japan) with excitation wave-
length of 428 nm and emission wavelength of 536 nm. All
treatments were in duplicate.
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Quantification of NF-kB activation and cytokines and
chemokines expression
Quantification of NF-kB activation in cells treated with LSA
and N-9 was detected by using NF-kB-luc reportor plasmid. The
plasmid was transiently transfected into VK2/E6E7 cells using
Lipofectamine 2000 transfection reagent. After 24 hours, LSA at
various concentrations and 10 mg/ml N-9 were added, and the
cells were cultured for another 24 hours. The level of NF-kB
activation was quantified by measurement of relative luminescence
units (RLU) as described above.
To determine IL-1a/b and IL-8 expression, VK2/E6E7 cells
were seeded into 24-well plates and treated with various
concentrations of LSA and 10 mg/ml N-9 as positive control.
After 6 hours incubation, the supernatants were harvested and
centrifuged to remove cellular debris and IL-1a/b and IL-8
concentrations were measured via ELISA. Their concentrations
were calculated by quadratic regression analysis based on
logarithmically transformed optical densities.
Structural modeling and docking analysis
The molecular models of LSA and LA were generated and
energy-optimized using ChemOffice Ultra 8.03 software. The
structures of JR-FL (R5 type) and HXB2 (X4 type) gp120s
containing V3 loops were reconstructed using Modeller 9v8
program [48] according to the template (PDB: 2B4C) and
sequence information from HIV Database (http://www.hiv.lanl.
gov/content/index). The charge density distribution of the
molecules was analyzed by Discovery Studio v2.1 software.
The molecular docking simulation of LSA onto the gp120 was
performed by Autodock 4.0 software [49]. A force-field-based
empirical free energy scoring function was used in this program.
The Lamarckian Genetic Algorithm (LGA) was used as a search
engine. The active site was defined using AutoGrid program. Both
ligands and the target protein were kept rigid. The resultant LSA-
gp120 conformations were ranked and categorized based on the
Intermolecular energy criteria. VMD 1.8.7 software was using to
view and prepare the figures [50].
Statistical analysis
Statistical analysis was performed using a two-tailed t test. The
significance level was set at P=0.05.
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